A prospective study using a combination of paclitaxel and bevacizumab in breast cancer discovered that VEGF-A expression was not correlated with treatment outcome, however the study revealed potential biological and prognostic roles of VEGF-VEGFR combinations 38. This evidence concerns the gene KDR and breast carcinoma.